<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00929942</url>
  </required_header>
  <id_info>
    <org_study_id>5237</org_study_id>
    <nct_id>NCT00929942</nct_id>
  </id_info>
  <brief_title>Biodegradable Stents in Lung Transplantation</brief_title>
  <official_title>Treatment of Benign Bronchial Airway Stenoses in Patients After Lung Transplantation With a Biodegradable Stent - a Proof of Concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ELLA-CS, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective observational trial involving 10 patients is planned. Intervention &quot;SX-ELLA&#xD;
      Stent Degradable DV Bronchial (DV Stent)&quot; will be implanted in the target lesion in general&#xD;
      anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway&#xD;
      complications will be measured by bronchoscopy and documented.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obstructive airway complications (OAC) (bronchial stenosis) are a significant problem in lung&#xD;
      transplantation (LTx), and a special subset of chronic graft dysfunction. The overall rate is&#xD;
      approximately 20% per recipient. Even though disobliteration (laser, argon-coagulation,&#xD;
      cryotherapy) or balloon dilatation (bronchoplasty) are performed there is a high rate of&#xD;
      recurrence. Self expandable metallic stents (SEMS) is one suggested treatment option after&#xD;
      failed initial therapy but have a high rate of re-stenosis (50-60%). Morbidity, the risk for&#xD;
      e.g. infection and atelectasis and lower long-term survival are often consequences in pts.&#xD;
      treated with SEMS. No surgical options aside from re-do-transplantation are available. OAC&#xD;
      are developing mostly in the time 3 - 6 months post Tx. The idea is a permanent but temporary&#xD;
      therapy with replacement character of the stenosis which is given in degradable bronchial&#xD;
      stents.&#xD;
&#xD;
      Hypothesis: New biodegradable bronchial stents are a successful treatment of benign bronchial&#xD;
      stenosis after lung transplantation. After stent placement is further disobliteration is less&#xD;
      frequently used during the next 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Show that DV stent can be safely placed in LTx recipients and are effective in relief of symptoms associated with OAC.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To demonstrate mucosal healing in the first 6 months after stent insertion.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Lung Transplantation</condition>
  <arm_group>
    <arm_group_label>DV Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention &quot;SX-ELLA Stent Degradable DV Bronchial (DV Stent)&quot; will be implanted in the target lesion in general anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway complications will be measured by bronchoscopy and documented.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SX-ELLA Stent Degradable DV Bronchial (DV Stent)</intervention_name>
    <description>Intervention &quot;SX-ELLA Stent Degradable DV Bronchial (DV Stent)&quot; will be implanted in the target lesion in general anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway complications will be measured by bronchoscopy and documented.</description>
    <arm_group_label>DV Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recurrent airway complication (obstructive or necrotic) after single-order double-lung&#xD;
             transplantation (at least twice balloon-dilatation or disobliteration therapy).&#xD;
&#xD;
          -  Patient at least 3 months after lung transplantation and followed in MHH outpatient&#xD;
             clinic.&#xD;
&#xD;
          -  Target lesion in the left or right main stem bronchus, intermediate bronchus, right or&#xD;
             left lower lobe, left upper lobe. Multiple lesions are eligible for inclusion and&#xD;
             treatment but DV-stent implantation in different target lesions should be at least 6&#xD;
             weeks apart.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast feeding women.&#xD;
&#xD;
          -  Patients who are using no double-barrier method of birth control.&#xD;
&#xD;
          -  Previous use of a metallic stent (SEMS).&#xD;
&#xD;
          -  Target lesion in the middle lobe bronchus, right upper lobe, carina or trachea.&#xD;
&#xD;
          -  Previous use of brachytherapy or topical mitomycin.&#xD;
&#xD;
          -  Pats. after heart-lung transplantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens T Gottlieb, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>June 29, 2009</study_first_submitted>
  <study_first_submitted_qc>June 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2009</study_first_posted>
  <last_update_submitted>July 20, 2011</last_update_submitted>
  <last_update_submitted_qc>July 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Karel Volenec</name_title>
    <organization>ELLA-CS, s.r.o.</organization>
  </responsible_party>
  <keyword>lung transplantation</keyword>
  <keyword>bronchial stenosis</keyword>
  <keyword>biodegradable stent</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

